The Japan’s Ministry of Health, Labour and Welfare has granted approval to Genmab's Epkinly (epcoritamab) for treating individuals with relapsed or refractory (R/R) follicular lymphoma who have undergone at least two prior therapies.
Biotechnology company Nona Biosciences has entered into a licensing agreement with the University of Alabama at Birmingham (UAB) to advance its B cell development research.
Perceive Pharma has secured $15m in a Series A funding round to expedite neuroprotective therapeutic development in glaucoma and other indications.
SpringWorks Therapeutics has selected Onco360 as national specialty pharmacy partner for Gomekli (mirdametinib).
Conduit Pharmaceuticals has announced a partnership with Charles River Laboratories to assess AZD1656 as well as its derivatives in a Systemic Lupus Erythematosus (SLE) model.
UK-based biotechnology company ExpressionEdits has announced a partnership and licensing agreement with Boehringer Ingelheim for optimising the expression of gene therapies.
The US Food and Drug Administration (FDA) has accepted to review Regeneron Pharmaceuticals’ resubmitted biologics license application (BLA) for linvoseltamab to treat adults with relapsed/refractory (R/R) multiple myeloma (MM).
Radiopharmaceutical company AdvanCell has expanded its partnership with Eli Lilly and Company to advance targeted alpha therapies for the treatment of cancer.
Norgine Pharmaceuticals has launched Pedmarqsi (sodium thiosulfate injection) commercially in Germany.
Essential Pharma and Clinigen have announced their Japan-Asia Pacific (JAPAC) collaboration expansion to improve patient access to four therapies in Korea and Japan.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.